During the past decade, MSD Norge A/S conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MSD Norge A/S" are "Advanced Cancer" (1 trials), "Advanced Solid Tumors" (1 trials), "Anal Cancer" (1 trials), "Anal Carcinoma" (1 trials) and "Bile Duct Cancer" (1 trials). Many other conditions were trialed in "MSD Norge A/S" in a lesser frequency.

Most popular intervention types in "MSD Norge A/S" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "ENG-E2 125 μg/300 μg vaginal ring" (1 trials), "LNG-EE 150 μg/30 μg COC" (1 trials) and "pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "MSD Norge A/S" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "MSD Norge A/S". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in MSD Norge A/S, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MSD Norge A/S, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".